A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma

Publication date: Jun 03, 2025

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma

Concepts Keywords
Biosciences Choroidal Melanoma
Brachytherapy Darovasertib
Investigator Enucleation
Proton GNA11
Randomized GNAQ
IDE 196
Melanoma
Neoadjuvant
Ocular Melanoma
Ocular Oncology
Ophthalmology
Plaque Brachytherapy
Protein Kinase C
Uveal Melanoma

Semantics

Type Source Name
disease MESH Uveal Melanoma
disease MESH Melanoma
pathway KEGG Melanoma

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *